The Innovation at a Glance
Patent US11532826B2, titled "Apparatus and method for battery passivation compensation in a medical device," describes a method to manage battery passivation in critical medical devices. The approach involves selectively applying discharge pulses to the battery during specific voltage thresholds to maintain optimal operating power. This technique enables a low-power mode processor activation, followed by voltage checks and controlled discharge pulses to ensure reliable device operation. By improving battery efficiency and stability, this innovation directly addresses challenges in sustaining uninterrupted power in medical applications.
The Inventor & Company Behind It
The patent is assigned to Roche Diabetes Care Inc, a well-established leader in diabetes management technology. Known for integrating innovative solutions in medical devices, Roche Diabetes Care Inc leverages its expertise in device reliability and patient-centric technology to enhance energy management capabilities. This patent fits squarely within their strategic focus on advancing medical device performance through sophisticated energytech innovations.
Market Opportunity
Battery efficiency and reliability are critical factors in medical devices, especially those that support chronic disease management such as diabetes. The patented method promises to enhance device lifespan and operational reliability by addressing battery passivation - a common issue causing voltage drops and device failures. Considering the expanding global demand for wearable and implantable medical technologies, this invention addresses a key pain point with direct commercial applicability and regulatory feasibility. Its positioning within energy management aligns with ongoing industry trends prioritizing durability and patient safety.
Growth Indicators
The patent has accrued 456 citations, indicating notable recognition and integration within related technological advancements. Its HIS score of 73.7 reflects significant innovation relevance and commercial promise within its niche. The combination of these metrics positions the patent as influential within the energy management domain for medical device applications. The established manufacturing and regulatory pathways further signal a readiness for market deployment and potential licensing opportunities.
Why IP Investors Are Watching
This patent encapsulates a technically credible solution to a pervasive challenge in medical device energy management. For IP investors, the value lies in its demonstrated technical sophistication combined with strong market alignment in the high-growth healthcare sector. With a focus on battery passivation compensation, the invention offers a durable competitive advantage vital for devices where power reliability is paramount. Its strategic fit within Roche Diabetes Care Inc's portfolio and the high citation count underscore its potential as a valuable licensing asset or foundational technology for future device iterations.
Get the Full Analysis
Patent US11532826B2 showcases a nuanced approach to battery management that could reshape reliability standards in medical devices. Investors with an interest in energy technologies and healthcare innovation will find this patent a compelling case study in bridging sophisticated engineering with practical market needs. For deeper insights into its technological impact and investment potential, IPI Terminal subscribers can access the comprehensive breakdown and related patent landscape analysis.